Cytek Biosciences (CTKB) Non-Current Assets (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Non-Current Assets data on file, last reported at $69.8 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 31.62% year-over-year to $69.8 million; the trailing twelve-month figure through Mar 2026 stood at $356.3 million (down 12.21% YoY), and the FY2025 full-year result was $69.5 million, down 32.51% from the prior year.
• Non-Current Assets for Q1 2026 stood at $69.8 million, roughly flat from $69.5 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $110.5 million in Q2 2025 and bottomed at $6.5 million in Q1 2022.
• The 5-year median for Non-Current Assets is $97.1 million (2023), against an average of $66.6 million.
• The widest annual swing landed in 2023, when Non-Current Assets soared 1138.08%; it then plunged 32.51% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $13.7 million in 2022, then soared by 648.41% to $102.4 million in 2023, then gained by 0.64% to $103.1 million in 2024, then slumped by 32.51% to $69.5 million in 2025, then rose by 0.38% to $69.8 million in 2026.
• The last three Non-Current Assets figures came in at $69.8 million (Q1 2026), $69.5 million (Q4 2025), and $106.4 million (Q3 2025), per Business Quant data.

Peer Comparison